Overview

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates if itraconazole causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Treatments:
Hydroxyitraconazole
Itraconazole